TELO
Telomir Pharmaceuticals, Inc.
1.10$
-2.6%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | -100.0% | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | -23.0% | +307.3% | +56.5% | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +10.8% | +246.5% | +107.8% | -7.7% | +51.6% | -60.7% | -22.4% | +294.5% | -26.0% | +5.5% | -57.1% | +25.2% | -87.3% | +1,673.0% | +70.7% | -63.9% | -4.9% | – | |
| – | – | +0.0% | +161.1% | +335.1% | +41.1% | +70.0% | +286.8% | +87.6% | +18.6% | +511.4% | -51.0% | -29.8% | +171.6% | -92.3% | +116.7% | -31.6% | +130.1% | – | |
| – | +10.4% | +233.3% | +108.6% | -0.9% | +195.3% | -33.1% | +13.0% | +77.6% | -23.0% | +307.3% | -51.6% | -24.7% | +131.7% | -77.4% | +86.2% | -51.2% | +69.5% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | +510.4% | +0.6% | +469.5% | -100.0% | – | – | +795,300.0% | -83.1% | +103.4% | -49.2% | -9.6% | +141.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.